SavedAdd your journal

Journals / İstanbul Kanuni Sultan Süleyman Tıp Dergisi / 2019 / Cilt: 11 - Sayı: 3

Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?

AA Amiloidozlu Hastalarda Serum FGF-23 Düzeyi Subklinik Aterosklerozun Göstergesi midir?

Alihan ORAL
Ali Rıza ODABAŞ
Kübra AYDIN BAHAT
Abdullah ÖZKÖK
Gülşah ŞAŞAK KUZGUN
Ali BAKAN
Sabahat ALIŞIR ECDER
Ömer Celal ELÇİOĞLU
Pages
171–177
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: CIMT levels were significantly higher in AA amyloidosis patients compared to the control group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Amyloid A (AA) amyloidosis is the most prevalent form of systemic amyloidosis, and is a serious condition characterized by protein-misfolding.
📊
Key Findings & Data:Cardiovascular involvement is known to be a significant manifestation of the disease and common carotid artery intima-media thickness (CIMT) assessment is one of the well-recognized tools for identification of subclinical atherosclerosis.
💡
Conclusion & Impact:Results: CIMT levels were significantly higher in AA amyloidosis patients compared to the control group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Amyloid A (AA) amyloidosis is the most prevalent form of systemic amyloidosis, and is a serious condition characterized by protein-misfolding. Cardiovascular involvement is known to be a significant manifestation of the disease and common carotid artery intima-media thickness (CIMT) assessment is one of the well-recognized tools for identification of subclinical atherosclerosis. It was reported that FGF-23 may be a significant factor associated with atherosclerosis development in patients with AA amyloidosis, as well as being an independent risk factor for increased CIMT. In this study, we aimed to investigate whether elevated FGF-23 levels might be associated with CIMT levels in AA amyloidosis patients. Method: We studied 63 patients with AA amyloidosis and 29 aged-matched healthy controls. All subjects’ demographic data were recorded and the following parameters were measured: erythrocyte sedimentation rate, C-reactive protein, creatinine, urea, albumin, calcium, phosphate, parathyroid hormone, FGF-23, eGFR, CIMT, blood pressure and BMI. Results: CIMT levels were significantly higher in AA amyloidosis patients compared to the control group (p

Özet

Amaç: Amiloidoz proteinlerin anormal katlantı oluşturması ile karekterize hayatı tehdit eden bir hastalıktır, Amyloid-associated (AA) amiloidoz sistemik amiloidozun en yaygın formudur. Kardiyovasküler tutulum amiloidozun en önemli klinik tezahürüdür ve karotis intima media kalınlığının ölçümü (KIMK) subklinik aterosklerozu tespit etmek için iyi tanımlanmış yöntemlerden birisidir. FGF-23 AA amiloidozda KIMK’dan bağımsız olarak subklinik ateroskleroz ile ilişkili olabileceği bildirilmiştir. Bu çalışmada amacımız, AA amiloidozlu hastalarda KIMK ile yükselmiş serum FGF-23 ile ilişkisinin olup olmadığına bakmaktı. Yöntem: Çalışmaya 63 AA amiloidozlu hasta ve 29 sağlıklı kontrol dahil ettik. Tüm olguların demografik verileri, eritrosit sedimantasyon hızı, Crp, kreatinin, üre, albumin, kalsiyum, fosfat, parathormon, FGF-23, eGFR, KIMK, kan basıncı ve vücut kitle indeksleri kayıt edildi. Bulgular: Karotis intima media kalınlığı AA amiloidozlu hastalarda kontrol grubuna göre anlamlı derecede fazlaydı (p

🔖

Cite This Article

ORAL, A., ODABAŞ, A. R., BAHAT, K. A., ÖZKÖK, A., KUZGUN, G. Ş., BAKAN, A., ECDER, S. A., ELÇİOĞLU, Ö. C. (2022). Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?. İstanbul Kanuni Sultan Süleyman Tıp Dergisi, Cilt: 11 - Sayı: 3, 171–177. https://ajindex.com/articles/551010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Immonen K, Finne P, Gronhagen-Riska C, Pettersson T, Klaukka T, Kautiainen H, et al. A marked decline in the incidence of renal replacement therapy for amyloido-sis associated with inflammatory rheumatic diseases - data from nationwide registries in Finland. Amyloid. 2011;18(1):25-8.
  2. Hazenberg BP, van Rijswijk MH. Where has secondary amyloid gone? Ann Rheum Dis. 2000;59(8):577-9.
  3. McAdam KP, Raynes JG, Alpers MP, Westermark GT, Westermark P. Amyloidosis: a global problem common in Papua New Guinea. P N G Med J. 1996;39(4):284-96
  4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18.
  5. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16(6):1788-93.
  6. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67(3): 1179-87.
  7. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 produc-tion. J Biol Chem. 2003;278(4):2206-11.
  8. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65(5):1943-6.
  9. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 miti-gates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205-15.
  10. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascu-lar disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc